Issue 6 · July 31, 2026 · 5 min read
Six Peptides Cleared the Panel
The vote that moves six peptides toward licensed pharmacies, and the months of process ahead
An advisory panel voted last week to move six peptides a step closer to licensed pharmacies, and it is already being reported as an approval. The gap between those two things is this week's story. Here's what's worth knowing:
Late dinners and dementia: Older people eating within two hours of bed three or more nights a week got a dementia diagnosis 17% more often, against a 6% base rate. Changed eating habits are an early sign, so the cause may run the other way.
Superagers carry the same risk genes: People over 80 who recall like someone decades younger carried the common Alzheimer's risk genes as often as ordinary-memory peers. A small study, so big genetic effects are ruled out and modest ones are not.
Hormone therapy tracked with stronger grip: Older women who took menopause hormone therapy had stronger hand grip, and the gap widened with age. Women chose it themselves. Grip predicts the rest of aging better than most single measures.
Low cholesterol reads differently after 65: Among Japanese adults over 65, the lowest bad cholesterol came with less heart disease but more disability and deaths. It often falls because illness is already under way. No reason to stop a statin.
An eye drug finally gets its own label: Doctors have long treated wet macular degeneration with a cancer drug repackaged for the eye. Regulators approved a purpose-made version, still months from sale. Same molecule, with a maker the agency oversees.
A painkiller with no opioid in it: A new pill beat placebo after surgery. Half on the higher dose needed no opioid, against a fifth on placebo. Company-run and halfway through testing. Every late-life operation is an opioid exposure you did not choose.
A virus that saves bladders: When surface bladder cancer stops responding to the standard bladder wash, removing the bladder is usually next. A cancer-killing virus cleared it in three of four. No comparison group, the maker paid for it, and it is still unapproved.
A gene panel you can order yourself: Labcorp starts selling a test you order yourself on August 3, reading 163 genes tied to inherited cancer, heart and metabolic risk. No price announced, no validation data published.
A $399 toilet sensor tracks your gut: Throne sells a clip-on sensor that tracks stool and hydration, with a $70-a-year membership on top. The cancer-detection pitch is not approved. The bathroom is the last unmonitored room in the house.
Concierge primary care at $69 a month: The PlushCare founders sell a $69-a-month membership that buys a doctor and a team to chase your appointments. Visits still bill through insurance. Coordination is most of what longevity clinics charge for.
Humana is dropping 600,000 people: Humana is dropping plans covering about 600,000 people in 2027 and has not said which counties. Their Medicare is safe; they pick another plan at open enrollment. Prevention only compounds if coverage is continuous.
How you feel about aging shows up in your health: Across couples over 50 followed a decade, people reported better health in years they felt better about aging. The direction of that arrow is anyone's guess.
Losing a spouse widens the circle: Among older Europeans who lost a spouse, the circle grew rather than shrank, especially for men, and satisfaction with it fell. Longevity research counts the circle. This is the argument for measuring how it feels.
The banana fight rests on eight men: People say banana ruins cocoa's antioxidants. In one 2023 trial paid for by a capsule maker, eight men got 84% less of them from a banana smoothie than a capsule. Whether banana spoils a berry smoothie went untested.
Featured
A shorter route from grey market to pharmacy shelf
Pharmacies that mix drugs to order may only use ingredients from a list the Food and Drug Administration (FDA) approves. Last week an FDA panel voted to recommend adding six peptides to that list, including the one sold for tissue repair (BPC-157). Three things follow:
The next step belongs to the FDA. The panel only advises. The agency still has to agree, write a rule and take comment, which runs months.
The FDA's own reviewers said no to all seven, and were overruled.
The supply route is the change. They would come from licensed pharmacies, not grey-market sellers. The evidence behind them is unchanged.
The reviewers' objection was more basic than thin evidence. These compounds have no settled chemical definition, so safety cannot be judged.
If a peptide is in your stack, treat any FDA-backed claim this month as marketing, and ask your doctor what is actually known.
More this week
More women got screened when they could do the swab themselves
Screening fails when people do not turn up. Singapore's clinics tried one change: a woman who turned down the nurse-done cervical swab was offered one she could do herself. Screening went from 43% to 57%, and most infections found were in women never screened before.
It counted infections at three months. Cancers prevented were never measured. The same test, handed over rather than performed, reached about 14 more women in every 100.
Lonelier people had worse memory later, and only one habit explained any of it
Lonelier people score worse on memory tests years later. The obvious explanation is that they move less and see fewer people. Researchers pooled three studies of more than 12,000 adults. That explanation does not hold: exercise and socializing accounted for none of the gap.
One thing did account for a slice. Lonelier people also did fewer mentally demanding things, and that covered about 7% of the memory gap. The other 93% is unexplained.
Nobody was assigned to be lonely, so early memory trouble could be driving the withdrawal instead. That leaves a narrower lesson than the usual advice. Mental demand seems to matter on its own.
On the radar
Medicare is ending the subsidy that held down prices on the drug plans people buy alongside basic Medicare, and what insurers asked to charge for 2027 is about 24% higher. No plan's own price is public yet; they post mid-to-late September, days before open enrollment. People skip doses when prices rise, and a cheap generic beats most of what gets sold as longevity. Shop then.
Go deeper at longevity.io